Send to a friend
RSS
google +
Print version

News (Illicit drugs)

This section on health in the EU has been created as a trustworthy gateway to a wide range of information and data on health-related issues and activities at both European, national and international level. The content is produced by the European Commission, the Member States of the EU and the European Economic Area (EEA), plus EU candidate countries; by international organisations; and by pan-European non-governmental organisations in the area of public health.

Effects of cannabidiol in the treatment of patients with Parkinson's disease: An exploratory double-blind trial    epda.eu.com

Study findings point to a possible effect of CBD in improving quality of life measures in PD patients with no psychiatric comorbidities; however, studies with larger samples and specific objectives a[...]

Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson's disease    epda.eu.com

Conclusions: Beta-blockers are associated with a lower risk of constipation, while dopaminergic treatments appear to increase risk of constipation.[...]

Cracking the code of the unspoken language    europa.eu

A Marie Curie research fellow, Oya Aran, has paved the way for the development of computer techniques that could automatically reveal meaning from body language and other visual cues, predict people'[...]

Dopaminergic medication does not improve stepping responses following backward & forward balance perturbations in Parkinson's    epda.eu.com

In conclusion, dopaminergic medication does not improve underscaling of stepping responses in PD. Therefore, other interventions are needed to improve these important defense postural reactions.[...]

Annual award ceremony to celebrate excellence in scientific writing on illicit drugs    europa.eu

The four winners of the 2014 EMCDDA scientific paper award will be honoured in Lisbon on 25 November at the fourth annual award ceremony hosted by the EU agency. The winners will receive a non-moneta[...]

Click and learn with the new-look Best practice portal from the European Monitoring Centre for Drugs and Drug Addiction    europa.eu

Targeted at practitioners and professionals, the portal is designed as a practical and reliable source of what works, and what doesn’t, in the areas of drug-related prevention, treatment, harm reduct[...]

Dopaminergic agents and nutritional status in Parkinson's disease    epda.eu.com

Results: In linear regression, total levodopa (l-dopa) equivalent daily dose (LEDD) was associated with worse MNA (B = 0.14, 95% CI = 0.26-0.02; P = 0.019). This association remained significant only[...]

The dopaminergic system in upper limb motor blocks (ULMB) investigated during bimanual coordination in Parkinson's disease (PD)    epda.eu.com

The current study investigated the occurrence of ULMB in PD participants without ('off') and with ('on') dopamine replacement using bimanual wrist flexionextension with external auditory cues.[...]

Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease    epda.eu.com

Study findings support the hypothesis that nigrostriatal dopaminergic deficit is associated with executive impairment, but not to memory or visuospatial impairment, in early PD.[...]

Effects of cannabidiol in the treatment of patients with Parkinson's disease: An exploratory double-blind trial    epda.eu.com

Study findings point to a possible effect of CBD in improving quality of life measures in PD patients with no psychiatric comorbidities; however, studies with larger samples and specific objectives a[...]

Dopaminergic medication does not improve stepping responses following backward & forward balance perturbations in Parkinson's    epda.eu.com

In conclusion, dopaminergic medication does not improve underscaling of stepping responses in PD. Therefore, other interventions are needed to improve these important defense postural reactions.[...]

Puerarin protects dopaminergic neurons in Parkinson's disease models    epda.eu.com

These data indicated that puerarin alleviated the oxidative stress and apoptosis in a PD cellular model, protected the dopaminergic neurons against rotenone toxicity and decreased the abnormal protei[...]

Mortality in Parkinson's disease is not associated with the severity of early dopaminergic defect    epda.eu.com

Results: Mortality rate was 56.8%. Although higher age (p 0.48).[...]

Dopaminergic agents and nutritional status in Parkinson's disease    epda.eu.com

Results: In linear regression, total levodopa (l-dopa) equivalent daily dose (LEDD) was associated with worse MNA (B = 0.14, 95% CI = 0.26-0.02; P = 0.019). This association remained significant only[...]

Disclaimer

The European Commission is solely responsible for information present on EU-level websites, information present in the Portal originated by the Commission. National-level information is provided by the Member States concerned and Member States are solely responsible for the accuracy of the information. Likewise, the European Commission is not responsible for information on non-governmental organisations and international organisations websites. The European Union is committed to user privacy. Read more concerning the Legal Notice.
Further questions can be answered through the Contact page. The Health-EU portal supports principles and measures to increase the credibility of information on the net. It complies with the HONcode standard for trustworthy health information: verify here.